secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001104659-24-059659
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax signs $1.3B Sanofi deal; Q1 revenue $94M, net loss $148M; removes going concern
--------------------------------------------------------------------------------

- Co-exclusive licensing with Sanofi includes $500M upfront, ~$70M equity, up to $700M milestones plus royalties per product.
- Q1 2024 revenue $94M (up from $81M YoY), net loss $148M (improved from $294M loss YoY).
- Reduced current liabilities by $831M in Q1; removed going concern notice.
- Updated 2024 guidance: Combined Revenue & Sanofi Payments $970M-$1,170M; Total Revenue $400M-$600M.
- Added standalone influenza arm to Phase 3 COVID-Flu combo trial; on track for H2 2024 initiation, potential 2026 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924059659/0001104659-24-059659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924059659/tm2414089d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer